These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11781689)

  • 1. Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families.
    Barkardottir RB; Sarantaus L; Arason A; Vehmanen P; Bendahl PO; Kainu T; Syrjäkoski K; Krahe R; Huusko P; Pyrhönen S; Holli K; Kallioniemi OP; Egilsson V; Kere J; Nevanlinna H
    Eur J Hum Genet; 2001 Oct; 9(10):773-9. PubMed ID: 11781689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
    Hartikainen JM; Kataja V; Pirskanen M; Arffman A; Ristonmaa U; Vahteristo P; Ryynänen M; Heinonen S; Kosma VM; Mannermaa A
    Clin Genet; 2007 Oct; 72(4):311-20. PubMed ID: 17850627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland.
    Sarantaus L; Huusko P; Eerola H; Launonen V; Vehmanen P; Rapakko K; Gillanders E; Syrjäkoski K; Kainu T; Vahteristo P; Krahe R; Pääkkönen K; Hartikainen J; Blomqvist C; Löppönen T; Holli K; Ryynänen M; Bützow R; Borg A; Wasteson Arver B; Holmberg E; Mannermaa A; Kere J; Kallioniemi OP; Winqvist R; Nevanlinna H
    Eur J Hum Genet; 2000 Oct; 8(10):757-63. PubMed ID: 11039575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes.
    Thorlacius S; Olafsdottir G; Tryggvadottir L; Neuhausen S; Jonasson JG; Tavtigian SV; Tulinius H; Ogmundsdottir HM; Eyfjörd JE
    Nat Genet; 1996 May; 13(1):117-9. PubMed ID: 8673089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haplotype analysis of the BRCA2 9254delATCAT recurrent mutation in breast/ovarian cancer families from Spain.
    Campos B; Díez O; Odefrey F; Domènech M; Moncoutier V; Martínez-Ferrandis JI; Osorio A; Balmaña J; Barroso A; Armengod ME; Benítez J; Alonso C; Stoppa-Lyonnet D; Goldgar D; Baiget M
    Hum Mutat; 2003 Apr; 21(4):452. PubMed ID: 12655574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000.
    Tryggvadottir L; Sigvaldason H; Olafsdottir GH; Jonasson JG; Jonsson T; Tulinius H; Eyfjörd JE
    J Natl Cancer Inst; 2006 Jan; 98(2):116-22. PubMed ID: 16418514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families.
    Oros KK; Leblanc G; Arcand SL; Shen Z; Perret C; Mes-Masson AM; Foulkes WD; Ghadirian P; Provencher D; Tonin PN
    BMC Med Genet; 2006 Mar; 7():23. PubMed ID: 16539696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients.
    Johannesdottir G; Gudmundsson J; Bergthorsson JT; Arason A; Agnarsson BA; Eiriksdottir G; Johannsson OT; Borg A; Ingvarsson S; Easton DF; Egilsson V; Barkardottir RB
    Cancer Res; 1996 Aug; 56(16):3663-5. PubMed ID: 8706004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A low proportion of BRCA2 mutations in Finnish breast cancer families.
    Vehmanen P; Friedman LS; Eerola H; Sarantaus L; Pyrhönen S; Ponder BA; Muhonen T; Nevanlinna H
    Am J Hum Genet; 1997 May; 60(5):1050-8. PubMed ID: 9150152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation.
    Bergman A; Einbeigi Z; Olofsson U; Taib Z; Wallgren A; Karlsson P; Wahlström J; Martinsson T; Nordling M
    Eur J Hum Genet; 2001 Oct; 9(10):787-93. PubMed ID: 11781691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The BARD1 Cys557Ser variant and breast cancer risk in Iceland.
    Stacey SN; Sulem P; Johannsson OT; Helgason A; Gudmundsson J; Kostic JP; Kristjansson K; Jonsdottir T; Sigurdsson H; Hrafnkelsson J; Johannsson J; Sveinsson T; Myrdal G; Grimsson HN; Bergthorsson JT; Amundadottir LT; Gulcher JR; Thorsteinsdottir U; Kong A; Stefansson K
    PLoS Med; 2006 Jul; 3(7):e217. PubMed ID: 16768547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA2 founder mutation in Slovenian breast cancer families.
    Krajc M; De Grève J; Goelen G; Teugels E
    Eur J Hum Genet; 2002 Dec; 10(12):879-82. PubMed ID: 12461697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.
    Machado PM; Brandão RD; Cavaco BM; Eugénio J; Bento S; Nave M; Rodrigues P; Fernandes A; Vaz F
    J Clin Oncol; 2007 May; 25(15):2027-34. PubMed ID: 17513806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Icelandic founder mutation BRCA2 999del5: analysis of expression.
    Mikaelsdottir EK; Valgeirsdottir S; Eyfjord JE; Rafnar T
    Breast Cancer Res; 2004; 6(4):R284-90. PubMed ID: 15217494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
    Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
    Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer progression and survival in BRCA2 mutation carriers.
    Tryggvadóttir L; Vidarsdóttir L; Thorgeirsson T; Jonasson JG; Olafsdóttir EJ; Olafsdóttir GH; Rafnar T; Thorlacius S; Jonsson E; Eyfjord JE; Tulinius H
    J Natl Cancer Inst; 2007 Jun; 99(12):929-35. PubMed ID: 17565157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of polymorphic markers in exclusion of BRCA1/BRCA2 mutations in families with aggregation of breast/ovarian cancers.
    Górski B; Debniak T; Jakubowska A; Cybulski C; Huzarski T; Byrski T; Złowocka E; Lubiński J
    J Appl Genet; 2003; 44(3):419-23. PubMed ID: 12923317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
    Díez O; Osorio A; Durán M; Martinez-Ferrandis JI; de la Hoya M; Salazar R; Vega A; Campos B; Rodríguez-López R; Velasco E; Chaves J; Díaz-Rubio E; Jesús Cruz J; Torres M; Esteban E; Cervantes A; Alonso C; San Román JM; González-Sarmiento R; Miner C; Carracedo A; Eugenia Armengod M; Caldés T; Benítez J; Baiget M
    Hum Mutat; 2003 Oct; 22(4):301-12. PubMed ID: 12955716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Origin and distribution of the BRCA2-8765delAG mutation in breast cancer.
    Palomba G; Cossu A; Friedman E; Budroni M; Farris A; Contu A; Pisano M; Baldinu P; Sini MC; Tanda F; Palmieri G
    BMC Cancer; 2007 Jul; 7():132. PubMed ID: 17640379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.